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Purpose. The health-related quality of life (HRQL) in chronic obstructive pulmonary disease (COPD) is worsened by frequent
exacerbations, and it can be affected by the concomitant presence of bronchial asthma (asthma-COPD overlap (ACO)). The
impacts of clinical factors associated with HRQL have not been compared in patients with COPD and ACO experiencing
exacerbations. Patients and Methods. Patients with COPD (N=705) and ACO (N=148) belonging to C and D groups according
to GOLD 2017 were recruited in stable condition. Demographic and clinical data were collected, spirometry was performed, and
patients rated the intensity of respiratory symptoms during the previous week. The COPD Assessment Test (CAT) and the EQ-
5D 3 level version (dimensions and visual analogue scale (VAS)) were used to assess disease-specific and generic HRQL,
respectively. Fisher’s exact test, χ2 test, ANOVA, and Pearson correlation were used for analysis (mean ± SD). Multiple linear
regression was applied to identify variables related to CAT and EQ-5D VAS scores. Results. The CAT and EQ-5D VAS scores
showed similarly low HRQL in COPD and ACO (20:7 ± 6:7 vs. 21:1 ± 6:3 (p = 0:52) and 56:2 ± 17:8 vs. 53:7 ± 18:2 (p = 0:11)).
There was a weak correlation between CAT and EQ-5D VAS scores (COPD: r = −0:345, p < 0:001; ACO: r = −0:245, p = 0:003).
More patients with COPD had problems related to anxiety/depression in EQ-5D (63.7% vs. 55.4%, p = 0:06). Pack-years exerted
a negative effect on HRQL measures both in ACO and COPD. Low HRQL in COPD was associated with female gender,
dyspnea, cough, gastroesophageal reflux disease, and arrhythmia, while in ACO, it was related to arrhythmia, hypertension, and
cough, but less to dyspnea. Conclusions. Patients with COPD and ACO experiencing exacerbations have low quality of life,
which is influenced by smoking history, symptoms, and comorbidities. These findings have important implications for the
development of therapeutic strategies to improve the health status of patients with these conditions.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by irreversible and progressive airflow limitation, the
presence of multiple comorbidities, and reduced quality of
life [1]. Several factors have been described to be negatively
related to the quality of life measures in COPD such as the
lower level of education, an unskilled profession, female
gender, and disease severity [2–4]. Comorbidities including
peripheral arterial disease, osteoporosis, depression, diabetes,
stroke, and myocardial infarction also exert an additional
unfavorable effect on the health status [2, 5–7]. Exacerbations
are important events in the course of COPD, and notably,
patients with frequent exacerbations suffer from poorer
quality of life [8, 9]. However, the influence of clinical factors
on health status in frequent exacerbators has not been
explored.
A subgroup of patients with COPD also show clinical
features of bronchial asthma and can be termed to have
asthma-COPD overlap (ACO) [10]. Patients with ACO are
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younger; they have a lower level of dyspnea and smoked less
than patients with COPD alone [11]. Of note, the rate of
exacerbation was shown to be unchanged [11, 12], but also
increased [13, 14] in ACO. Compared to COPD, patients
with ACO have more severe airway obstruction [15, 16],
more severe wheezing [16], and a different set of comorbidi-
ties [17]. Reports on quality of life in ACO vs. COPD showed
contradictory findings [12, 18], and health measures have not
been studied in frequent exacerbators with overlap disease.
Thus, we aimed to investigate the health-related quality of
life (HRQL) in patients with COPD and ACO who experience
multiple disease relapses. We compared the clinical features
and the disease-specific and a generic HRQL in patients with
COPD and ACO belonging to groups C and D as classified
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) recommendation [1]. Furthermore,
the influence of demographic and clinical variables, as well as
comorbidities on the health status of patients, was also studied.
2. Material and Methods
2.1. Patients and Study Design. Patients were recruited by 71
respiratory specialists during regular control visits at outpatient
pulmonology centers in Hungary between 01 November 2017
and 31 March 2018. Inclusion criteria were age > 18 years,
COPD diagnosed >1 year ago by a respiratory specialist (as
postbronchodilator FEV1/FVC < 0:70) [1], and exacerbation
history equivalent to groups C or D according to GOLD docu-
ment 2017 [1]. ACO was established when patients showed
overlapping clinical characteristics of COPD and bronchial
asthma [10] together with a concomitant diagnosis of bronchial
asthma established at least one month prior to inclusion.
Patients with ACO had a positive bronchial hyperreactivity or
reversibility testing (>12% or 200ml after the inhalation of
400μg salbutamol) in the past. Exclusion criteria were the pres-
ence of severe and untreated comorbidity, inability to fill out
the HRQL questionnaires, current systemic steroid or antibi-
otic treatment, restrictive ventilatory failure, severe cardiac fail-
ure, current tuberculosis infection, and active cancer.
The study had a noninterventional longitudinal design.
During the first visit, detailed clinical characteristics,
information on drug side effects, spirometric variables, and
data on symptoms and HRQL were collected, inhaler
technique was checked and corrected when necessary. At
later visits (after 1 month and 3 months), the inhaler tech-
nique was rechecked, education on inhaler use was repeated,
and spirometric values, symptom scores, and HRQL vari-
ables were recorded. Data of patients with three completed
visits were collected for statistical analysis (N = 944). During
data clearance, 91 patients were excluded for not meeting the
inclusion criteria for exacerbation number (N = 853). In the
present work, data only from the first visit were analyzed in
a cross-sectional manner.
The study was approved by the Hungarian Medical
Research Council (46367-4/2017/EKU) and the National
Institute of Pharmacy and Nutrition (46402-5/2017). Each
patient signed a written informed consent. All work was con-
ducted in accordance with the Declaration of Helsinki (1964).
2.2. Data Collection. Demographic and basic clinical data
were recorded (age, gender, smoking history, number of
moderate, and severe past exacerbations according to catego-
ries). Former smoking was defined as smoking stopped at
least 6 months earlier. Educational level was noted as
completed higher education (higher), completed secondary
education (middle), and completed or uncompleted primary
education (low). Height, weight, and prebronchodilator spi-
rometry (FVC, FEV1) were measured [19]. Body mass index
(BMI) was calculated, and patients were categorized into four
groups [20]: underweight (<20 kg/m2), normal weight (20 to
24.9 kg/m2), overweight (25 to 29.9 kg/m2), and obese
(≥30 kg/m2). Current inhaled therapy regimens (classes of
drugs) and the use of short-acting bronchodilators in the past
week (≤1/week, 2-3/week, >3/week) were recorded.
Self-reported comorbidities were noted according to pre-
defined categories (gastroesophageal reflux disease (GERD),
ischemic heart disease, hypertension, myocardial infarction,
arrhythmia, heart failure, cerebrovascular event, osteoporo-
sis, diabetes, glaucoma, and chronic bronchitis). Arrhythmia
was defined as an existing chronic arrhythmia or a previous
intermittent episode. A previous stroke or a past intermittent
cerebrovascular episode was considered a cerebrovascular
event. Chronic bronchitis was defined as at least 3 months
of productive coughing in 2 or more consecutive years, and
it was assessed only in patients with COPD.
Patients rated their level of dyspnea using the Modified
British Medical Research Council (mMRC) Questionnaire
[21], and they were asked to assess the intensity of symptoms
(dyspnea at rest, dyspnea during daily activities, and cough)
in the past week on a scale from 0 to 10, where 0 meant no
symptoms and 10 referred to unbearable symptoms. Sputum
production in the past week was also reported: no sputum
(0), a small amount (1), a moderate amount (2), and a signif-
icant amount (3).
Quality of life was measured with the disease-specific
COPD Assessment Test (CAT), which is a validated 8-item
tool used for monitoring COPD [22]. Symptoms were self-
assessed by patients on a scale from 0 to 5; the maximal over-
all score is 40 with higher scores referring to higher symptom
burden.
The EQ-5D-3L (3 level version) and the EQ-5D-VAS
(visual analogue scale) were applied to evaluate the generic
health status [23]. The EQ-5D-3L comprises of 5 dimensions:
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. In each dimension, the disability can be
rated by the patients on 3 levels: no problems (1), some
problems (2), and extreme problems (3). Due to the lack of
available value sets representative for the Hungarian popula-
tion, a utility score could not be calculated; therefore, the
dimensions were individually analyzed. Patients graded their
today health using the VAS in the form of a 20 cm vertical
line ranging from 0 to 100, where 100 represents the best
imaginable and 0 the worst imaginable health status.
2.3. Data Analysis. Categorical variables were analyzed with
the Fisher exact and χ2 tests (combined with post hoc analy-
sis). Continuous variables showed Gaussian distribution and
were analyzed using a t-test, ANOVA, and Pearson
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correlation and presented through their means and standard
deviations (SD). Multiple linear regression was applied to iden-
tify clinical variables related to CAT and EQ-5D VAS. The
SPSS 19.0. software (IBM, Armonk, NY, US) was applied for
statistical analysis; p values < 0.05 were considered significant.
3. Results
3.1. Demographic Variables in Patients with COPD and ACO.
Among the 853 patients included in the study, 18% and 82%
had ACO and COPD alone, respectively (Table 1). Most
patients belonged to GOLD group D (COPD patients C/D:
5.0/95.0%, ACO patients: group C/D: 3.4%/96.6%; p = 0:41
). There was a trend for more male patients with COPD.
The BMI was higher in patients with ACO with an increased
ratio of obese patients, while we observed a tendency for
more underweight patients with COPD. As expected, there
were more current smokers with COPD, and more patients
were nonsmokers in the ACO group; however, the pack-
years were similar in the two groups. FEV1 and FEV1/FVC
were lower in COPD alone. Inhaled therapy regimens with
ICS (inhaled corticosteroid) were more frequently used by
patients with ACO, while long-acting muscarinic antagonist
and long-acting beta2-agonist (LAMA+LABA) products
were applied by more patients with COPD alone. We noted
a trend for an increased number of hypertension cases and
a higher overall burden of comorbidities in COPD. No differ-
ence was noted in age, educational level, and the number of
COPD-related emergency room visits and hospitalizations
between the two groups.
3.2. Quality of Life and Symptoms in Patients with COPD and
ACO. There was a significant but weak correlation between
CAT and EQ-5D VAS scores in patients with COPD
(r = −0:345, p < 0:001; Figure 1(a)) and ACO (r = −0:245, p
= 0:003; Figure 1(b)). The CAT score showed a similarly
low disease-specific quality of life in both groups, which is
line with the predominance of the GOLD D group patients
in the populations (Table 2). The EQ-5D VAS tool demon-
strated a mean decrease of 2.5 points in ACO compared to
COPD; however, it did not reach statistical significance. A
trend for more severe anxiety and depression was noted in
patients with COPD, and the proportion of patients with
any problems (some or extreme problems) in the anxiety/de-
pression dimension was increased in COPD vs. ACO (63.7%
vs. 55.4%, p = 0:06). We found no difference in the health
status between the two groups analyzed according to other
EQ-5D dimensions (Table 2).
The intensity of respiratory symptoms and the use of short-
acting bronchodilator in the past week were similar in the two
groups (Table 2). Of note, approximately half of the patients
needed to use a reliever medication more than three times in
the previous week, highlighting the high symptom burden.
Interestingly, the CAT score was increased in patients
with ACO on LAMA+LABA therapy compared to COPD
patients on dual long-acting bronchodilators (Table 3). Data
on mono-LAMA and mono-LABA use were not analyzed
due to the low number of patients in the ACO group (n = 2
and n = 0, respectively).
3.3. Clinical Variables Associated with Health Status in
Patients with COPD. In patients with COPD, a lower
disease-specific quality of life, denoted by a higher CAT
score, was associated with pack-years and the increased
number of severe exacerbations in the past 12 months
(Table 4). The intensity of dyspnea either at rest or during
daily activities and the intensity of cough were related to
higher CAT scores; however, the amount of sputum showed
no association. Among the comorbidities, only GERD was
associated with higher CAT scores.
As shown by the EQ-5D VAS score, a better generic
HRQL was linked to a higher level of education, while it
was negatively associated with female gender, pack-years,
arrhythmia, and dyspnea at rest. There was a trend for worse
health status in patients with the frequent use of reliever
medications.
3.4. Clinical Variables Associated with Health Status in
Patients with ACO. In patients with ACO, an increased CAT
score was associated with the high intensity of cough in the
past week (Table 4). In addition, the frequent use of reliever
medications was related to higher CAT scores, and arrhythmia
showed a trend for an increase in the CAT score. Unexpect-
edly, we found a tendency between lower CAT scores and a
high number of previous severe COPD-related exacerbation
and the presence of obesity (trend toward significance).
The EQ-5D VAS score was positively associated with a
higher level of education. There was a negative relationship
between the general health status and pack-years, arrhyth-
mia, and the frequent use of short-acting bronchodilators.
Moreover, we observed a trend for a negative association
between the EQ-5D VAS score and hypertension and the
intensity of dyspnea at rest.
4. Discussion
Exacerbations in COPD are associated with worse and
deteriorating quality of life [8, 24]. A higher number of hos-
pitalizations due to respiratory symptoms [13, 14] and a
lower HRQL [18] were recorded in patients with ACO com-
pared to subjects with asthma or COPD alone. The mecha-
nism of ACO is currently incompletely understood, and
more research is needed to identify its specific clinical and
physiological characteristics [10]. In the present study, we
focused on patients with COPD and ACO with a history of
past exacerbations and found that both groups have similarly
low HRQL, which is associated with partly shared clinical
variables including the burden of respiratory symptoms and
comorbidities.
The clinical characteristics of patients with ACO and
COPD showed differences. We observed a higher number of
women, increased BMI, and somewhat better FEV1/FVC
among patients with ACO, which corroborate previous find-
ings [25]. Interestingly, airway obstruction was less severe in
patients with ACO, while previous studies reported decreased
[15] or similar [25] FEV1 compared to patients with COPD.
These discrepancies can be explained by the different patient
population in our study: (i) we also included never smokers,
(ii) patients were diagnosed by respiratory specialists, and
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(iii) patients belonged only to GOLD groups C and D. In
spite of the higher FEV1, dyspnea was as severe in ACO as
in COPD (either assessed by mMRC or symptom scores),
which might be related to the heightened sensation of
dyspnea in this group [26]. We observed a higher prevalence
of hypertension and arrhythmia in COPD than in ACO as
also shown by others [12].
We did not find a difference in CAT scores between
patients with COPD and ACO, which supports previous
findings in a cohort with similar symptom burden [27].
Nonetheless, Kurashima et al. found higher CAT scores in
Japanese patients with ACO who showed higher scores
for cough, phlegm, and dyspnea, but the average CAT
score and exacerbation frequency were lower than in our
cohort [26]. Furthermore, Park et al. did not show a differ-
ence in the disease-specific quality of life between ACO and
COPD in a Korean cohort using the CAT tool; however,
the Saint George’s Respiratory Questionnaire (SGRQ)
could detect better HRQL in ACO [12]. On the contrary,
ACO was associated with a worse health status assessed
by the SGRQ in a US population comprised of patients
with different ethnic groups [25]. These and our data
suggest that besides exacerbation history, disease-specific
health status in ACO might also be influenced by the
genetic background of patients.
Our study provides novel data on the relationship between
inhaled therapies and HRQL in ACO. We found that patients
on dual long-acting bronchodilators have worse CAT scores
compared to patients with combination therapies including
ICS. This supports the use of ICS in ACO as also stated in
the consensus-based document available in the Global
Strategy for AsthmaManagement and Prevention report [10].
Our results demonstrate that different clinical factors
modulate disease-specific quality of life in COPD and ACO
with exacerbations. The negative influence of smoking
history [28], the intensity of dyspnea [29], and the exacerba-
tion number [30] in COPD have already been known, but the
unfavorable effect of gastroesophageal reflux disease on CAT
score has not been described before. It can be speculated that
GERD worsens cough, which is also associated with higher
CAT in our cohort; however, further research should give
better insight into the mechanism of GERD and HRQL.
Contrary to COPD, dyspnea is not associated with CAT
scores in ACO, which was rather related to cough as also
noted by others [26]. In ACO, the number of severe exacer-
bations is not associated with higher CAT scores, which
Table 1: Demographic and clinical data of patients with COPD and
ACO.
COPD
(n = 705)
ACO
(n = 148) p value
Men 50.9% 42.6% 0.065
Age (years) 63:7 ± 9:5 62:3 ± 11:2 0.109
Body mass index (kg/m2)
(all patients)
27:8 ± 6:6 29:0 ± 6:2 0.043
Body mass index
(categories)
0.048
<20 9.9% 5.4% 0.082
20-24.9 28.6% 21.6% 0.087
25.0-29.9 27.9% 30.4% 0.549
>30 33.6% 42.6% 0.038
Smoking status <0.001
Current 54.5% 39.2% <0.001
Past 36.0% 35.1% 0.834
Never 9.5% 25.7% <0.001
Pack-years 32:3 ± 17:5 31:7 ± 19:4 0.717
Educational level 0.104
Low 44.4% 43.9%
Medium 51.1% 47.3%
High 4.5% 8.8%
No. of hospitalizations and
ER visits due to respiratory
symptoms in the past year
0.932
0 62.4% 60.8%
1 27.7% 29.1%
≥2 9.9% 10.1%
FVC (L) 2:22 ± 0:70 2:30 ± 0:88 0.239
FVC (% reference) 69:4 ± 17:6 71:3 ± 18:3 0.237
FEV1 (L) 1:25 ± 0:46 1:34 ± 0:58 0.040
FEV1 (% reference) 48:6 ± 14:9 52:3 ± 16:2 0.007
FEV1/FVC 0:56 ± 0:10 0:58 ± 0:10 0.037
Inhaled therapy <0.001
LAMA 3.1% 1.4% 0.238
LABA 0.7% 0% 0.303
LAMA+LABA 49.2% 25.7% <0.001
LABA+ICS 3.3% 16.9% <0.001
LABA+LAMA+ICS 43.7% 56.1% 0.006
Comorbidities
Gastroesophageal reflux 22.4% 21.0% 0.696
Ischemic heart disease 22.4% 18.9% 0.350
Hypertension 60.9% 52.7% 0.066
Myocardial infarction 4.5% 2.7% 0.312
Arrhythmia 10.8% 6.1% 0.083
Heart failure 7.8% 5.4% 0.311
Cerebrovascular event 5.7% 4.7% 0.647
Osteoporosis 7.4% 9.5% 0.646
Diabetes 12.3% 14.2% 0.167
Glaucoma 2.0% 0.7% 0.270
Table 1: Continued.
COPD
(n = 705)
ACO
(n = 148) p value
Benign prostate
hyperplasia
13.4% 11.1% 0.623
Total number of
comorbidities
1:63 ± 1:49 1:40 ± 1:31 0.090
Data are shown as mean ± SD. Data were analyzed with Fisher’s exact test, t
-test, and χ2 tests (with post hoc analysis). ACO: asthma-COPD overlap; ER:
emergency; FVC: forced vital capacity; FEV1: forced expiratory volume in the
1st second; LAMA: long-acting muscarinic antagonist; LABA: long-acting
beta2-agonists; ICS: inhaled corticosteroid.
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could be explained by better recovery induced by the better
response to systemic steroids in this population compared
to patients with COPD. The association of the frequent
use of reliever medications and arrhythmia to CAT scores
in ACO might be linked, and it raises attention to the
speculative negative effects of reliever abuse on disease-
specific HRQL.
The EQ-5D VAS scores were low for both ACO and
COPD confirming similarly reduced health status in these
groups. This extends previous findings, which showed that
patients with ACO have reduced health status, comparable
to COPD patients of the exacerbator phenotype [31].
Interestingly, most patients reported some problems in all
five dimensions of the EQ-5D, and there was a tendency for
a higher proportion of COPD patients with any problems
of depression and anxiety. In a Polish COPD cohort, an
increased prevalence of both anxiety and depression was
noted for frequent exacerbators compared to patients with
ACO [32], which is verified in our cohort of exacerbation-
matched patients.
The factors influencing generic health, as reflected by
EQ-5D VAS scores, in patients with ACO and COPD are
partly shared. We show that contrary to smoking status,
which does not influence HRQL in this and in other COPD
cohorts [7], pack-years do exert a negative influence on
EQ-5D VAS score in both groups. Dyspnea at rest is the only
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Figure 1: Correlation between the CAT and the EQ-5D VAS scores: (a) COPD, r = −0:345, p < 0:001; (b) ACO, r = −0:245, p = 0:003
(Pearson correlation).
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symptom related to health status both in COPD and ACO,
which might be partly explained by the altered dimensions
of dyspnea in patients with COPD [29]. Prebronchodilator
FEV1 did not show a relation to HRQL; however, other lung
function values including specific airway resistance and
readouts of hyperinflation could better evaluate the beneficial
effect of bronchodilators on dyspnea and quality of life [33],
but these parameters were not measured in our study. We
corroborated previous findings on the negative effect of
cardiovascular comorbidities in COPD [2] by showing that
HRQL is associated with cardiovascular comorbidities
including arrhythmia (COPD and ACO) and hypertension
(ACO). Like others [4], we also found that female patients
have lower HRQL if they have COPD, but not ACO.
However, higher classes of education are associated with
better HRQL in both groups as already shown for COPD [7].
We analyzed the correlation between the disease-specific
and generic HRQL measures in ACO for the first time. We
found that the CAT and EQ-5D VAS scores were more
weakly correlated in ACO than in COPD, which can be
explained by the higher influence of nonrespiratory
symptoms on the general health status in ACO.
Our study was performed in a large cohort of COPD
patients diagnosed by respiratory specialists; however, it has
few limitations. First, comorbidities which are known to
influence HRQL in COPD and might also affect it in ACO
such as psychiatric disorders and peripheral artery disease
[7] were not studied. Second, comorbidities were self-
reported by patients, which might limit their validity. Third,
utility score could not be calculated for EQ-5D-3L. Further-
more, we did not measure bronchial reversibility, although
a subgroup of patients with COPD alone show a clinically
relevant bronchial reversibility linked with inflammatory
processes [34]. Importantly, reversibility was related to
dyspnea and quality of life in a recent COPD cohort [35].
5. Conclusions
In conclusion, patients with COPD and ACO experiencing
exacerbations have similarly reduced disease-specific and
Table 2: Symptoms and quality of life in patients with COPD and ACO.
COPD ACO p value
CAT score 20:7 ± 6:7 21:1 ± 6:3 0.522
EQ-5D VAS score 56:2 ± 17:8 53:7 ± 18:2 0.110
EQ-5D scores
Mobility 1:54 ± 0:52 1:51 ± 0:54 0.511
Self-care 1:48 ± 0:56 1:48 ± 0:58 0.928
Usual activities 1:83 ± 0:55 1:89 ± 0:53 0.304
Pain/discomfort 1:74 ± 0:57 1:69 ± 0:55 0.318
Anxiety/depression 1:76 ± 0:66 1:66 ± 0:66 0.074
mMRC score 2:5 ± 0:8 2:4 ± 0:8 0.692
Severity of symptoms in the past week
Dyspnea at rest 3:64 ± 3:06 3:67 ± 3:33 0.900
Dyspnea during daily activities 4:27 ± 2:98 4:60 ± 2:92 0.216
Cough 5:09 ± 2:19 4:93 ± 2:41 0.425
Sputum production 1:67 ± 0:64 1:69 ± 0:64 0.738
Use of short-acting bronchodilators in the past week (% all patients) 0.274
≤1 22.5% 20.4%
2-3 29.5% 23.1%
>3 48.0% 56.5%
Data are shown asmean ± SD. Data were analyzed with t-test, Mann-Whitney test, and χ2 test. CAT: COPDAssessment Test; mMRC:Modified BritishMedical
Research Council Questionnaire.
Table 3: Quality of life measures according to maintenance inhaled therapy.
CAT p value EQ-5D VAS score p value
COPD ACO COPD ACO
LAMA+LABA 20:5 ± 6:9 23:0 ± 6:3 0.033 59:4 ± 16:1 59:5 ± 15:3 0.963
LABA+ICS 20:4 ± 6:0 20:4 ± 6:0 0.958 50:9 ± 23:9 47:8 ± 18:4 0.619
LABA+LAMA+ICS 20:9 ± 6:8 20:4 ± 6:3 0.545 52:9 ± 18:3 53:4 ± 18:3 0.853
Data are shown as mean ± SD. Data were analyzed with t-test.
6 Pulmonary Medicine
generic qualities of life, but patients with COPD seem to have
more severe problems in the dimension of anxiety and
depression. Pack-years and the frequent use of short-acting
bronchodilators exert a negative effect on HRQL measures
both in ACO and COPD. HRQL is influenced by symptoms
and comorbidities as well. Low HRQL in COPD is associated
with the female gender, dyspnea, cough, GERD, and arrhyth-
mia, while it is related to arrhythmia, hypertension, and
cough, but less to dyspnea in ACO. Our results aid the devel-
opment of complex therapeutic strategies to improve the
health status of patients with COPD and ACO.
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Body mass index (kg/m2)
<20 0.549 1.820 -1.351 -0.773
20-24.9 Ref. Ref. Ref. Ref.
25.0-29.9 0.863 -2.160 -1.891 -2.669
>30 0.769 -0.471 -3.407d -7.136
Smoking status
Current 0.781 0.653 -0.034 -0.491
Ex-smoker Ref. Ref. Ref. Ref.
Pack-years 0.029a -0.094a -0.006 -0.238a
Educational level
Low Ref. Ref. Ref. Ref.
Medium -0.452 4.208b -0.594 3.009
High -0.903 1.441 -1.046 10.372e
No. of hospitalizations and
ER visits due to exacerbation
in the past year
0 Ref. Ref. Ref. Ref.
1 -0.722 0.058 -2.598 -0.262
≥ 2 2.257b -0.443 -6.772a -6.430
FEV1 (% reference) -0.024 0.072 -0.049 0.143
Comorbidities
Absence of comorbidity Ref. Ref. Ref. Ref.
Gastroesophageal reflux 1.578b 1.118 0.477 4.149
Ischemic heart disease -1.104d 0.979 -0.476 -0.198
Hypertension 0.098 2.473 1.249 -6.218e
Past myocardial infarction 1.409 5.494 9.143 -9.305
Arrhythmia 0.674 -6.298a 5.589e -15.852a
Heart failure 0.830 -0.031 0.993 -7.320
Past cerebrovascular event -0.404 -3.174 -1.922 -6.255
Osteoporosis -1.508 0.213 -0.183 4.052
Diabetes -0.431 -0.235 -3.067 -1.123
Glaucoma 2.869 -1.372 -1 -1
Chronic bronchitis -1.341a 2.583 -2 -2
Severity of symptoms in
the past week
Dyspnea at rest 0.573c -1.286c 0.150 -1.302d
Dyspnea during daily
activities
0.353c -0.398 0.351 0.808
Cough 0.508c 0.405 0.939a -0.143
Sputum production,
amount small
Ref. Ref. Ref. Ref.
Medium 0.331 -2.587 0.120 1.664
Significant 0.307 -0.706 -1.806 -8.841
Table 4: Continued.
COPD ACO
CAT
EQ-5D
VAS
CAT
EQ-5D
VAS
Use of short-acting
bronchodilators in the
past week (% all patients)
≤1 Ref. Ref. Ref. Ref.
2-3 0.006 2.258 3.870 -11.269a
>3 1.194 -3.831d 4.593a -6.393
ap < 0:05, bp < 0:01, cp < 0:001, dp = 0:07, ep = 0:09. 1: not analyzed due to
missing data; 2: not assessed in the ACO group; Ref.: reference category.
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